Overview
- The National Institute for Health and Care Excellence has judged insulin efsitora alfa, marketed as Onswik by Eli Lilly, to be good value for money in draft guidance.
- Clinical trials reported that the long‑acting formulation can control blood glucose as effectively as daily insulin when given once a week.
- Regulators have not yet completed approvals and NHS England has not committed to a nationwide roll‑out, so access on the NHS remains uncertain.
- Diabetes UK has urged that any adoption be supported by clear clinical guidance, staff training and measures to ensure fair access for people who rely on help with injections.
- The drug could affect large numbers of people because about 4.2 million in the UK have type 2 diabetes and roughly one in four need insulin, with rising rates in younger adults increasing demand.